Amitriptyline (Elavil) is a tricyclic antidepressant (TCA) used for depression, neuropathic pain, migraine prevention, and insomnia. It works by potently inhibiting the reuptake of both norepinephrine and serotonin, while also strongly blocking muscarinic (anticholinergic) and histamine H1 receptors. It has a narrow therapeutic index — the difference between a therapeutic and toxic level is small — and overdose causes life-threatening cardiac toxicity. It is on the Beers Criteria list of drugs considered potentially inappropriate for elderly patients due to its anticholinergic burden.
Amitriptyline
Uses & FDA Indications
Amitriptyline was introduced in the 1960s and remains widely used despite the development of safer antidepressants. It is FDA-approved for the treatment of major depressive disorder in adults. Its sedating properties are frequently leveraged off-label, and it has become a standard treatment for several pain conditions where its analgesic properties operate independently of antidepressant effects.
FDA-approved indications include major depressive disorder (MDD) in adults. Off-label uses with significant evidence include neuropathic pain (diabetic neuropathy, postherpetic neuralgia), migraine prophylaxis, fibromyalgia, and insomnia. In pain and headache management, lower doses are often used than those needed for antidepressant effect, and clinical benefit may appear within 1–2 weeks.
Amitriptyline is generally not considered a first-line antidepressant in current guidelines due to its side effect burden and overdose risk. SSRIs and SNRIs have largely replaced TCAs for depression. However, amitriptyline remains preferred in specific situations — particularly migraine prevention and neuropathic pain — where its multi-receptor profile confers unique benefits.
How It Works
Amitriptyline is a tertiary amine tricyclic antidepressant with one of the broadest receptor profiles in pharmacology. Its primary antidepressant mechanism is inhibition of the reuptake transporters for norepinephrine (NET) and serotonin (SERT) in presynaptic neurons, increasing the synaptic availability of both monoamines.
Beyond reuptake inhibition, amitriptyline is a potent antagonist at muscarinic acetylcholine receptors (producing anticholinergic effects), histamine H1 receptors (producing sedation and weight gain), and alpha-1 adrenergic receptors (producing orthostatic hypotension). It also blocks fast sodium channels in the heart — the mechanism behind its cardiac toxicity in overdose.
Amitriptyline is metabolized by CYP2D6 to nortriptyline, which is itself an active antidepressant TCA. Poor metabolizers of CYP2D6 (a genetic trait found in ~7–10% of Caucasians) accumulate higher levels of amitriptyline, while ultra-rapid metabolizers may have subtherapeutic levels. Pharmacogenomic testing can inform TCA dosing in complex cases.
NARROW THERAPEUTIC INDEX: Amitriptyline has a narrow therapeutic index. Toxic plasma levels are not far above therapeutic ones. Tricyclic antidepressant overdose is a medical emergency — cardiac arrhythmias (QRS widening, ventricular tachycardia), hypotension, and seizures can be fatal. Prescribers routinely limit prescription quantities in patients at risk of self-harm.
Side Effects
Common
- Sedation / drowsiness — significant and often dose-limiting; frequently exploited therapeutically for insomnia
- Dry mouth — very common anticholinergic effect; can cause dental problems with chronic use
- Constipation — anticholinergic; monitor for serious ileus in high doses
- Weight gain — H1 blockade increases appetite; one of the most common reasons patients discontinue
- Orthostatic hypotension — alpha-1 blockade causes dizziness upon standing; fall risk especially in elderly
- Blurred vision, urinary retention — anticholinergic effects
- Sexual dysfunction — decreased libido, delayed orgasm
Serious
- Cardiac conduction abnormalities — QT prolongation, PR prolongation, QRS widening; risk of ventricular arrhythmias, particularly in overdose
- Serotonin syndrome — when combined with other serotonergic agents (MAOIs, triptans, SSRIs, SNRIs, tramadol); potentially life-threatening
- Suicidality (black box warning) — FDA black box warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25) during initial treatment
- Anticholinergic toxicity / delirium — especially in elderly; confusion, agitation, hallucinations
- Seizure lowering — lowers seizure threshold
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, selegiline) | Risk of severe serotonin syndrome and hypertensive crisis — potentially fatal. Absolute contraindication. Allow 14 days washout between MAOI and TCA. | Contraindicated — never combine |
| SSRIs / SNRIs | Additive serotonergic effects increase serotonin syndrome risk. CYP2D6 inhibitors (fluoxetine, paroxetine) also substantially raise amitriptyline plasma levels. | High — combination requires careful monitoring; generally avoid fluoxetine/paroxetine co-administration |
| QT-Prolonging Drugs (antipsychotics, methadone, fluoroquinolones, ondansetron) | Additive QTc prolongation increases arrhythmia risk. | Moderate-High — review cardiac risk; baseline ECG recommended |
| CNS Depressants (opioids, benzodiazepines, alcohol, antihistamines) | Additive CNS depression — sedation, respiratory depression, impaired psychomotor function. | Moderate — use with caution; counsel patient on driving impairment |
| Anticholinergic Drugs (bladder agents, antihistamines, antipsychotics) | Additive anticholinergic burden — dry mouth, urinary retention, constipation, confusion, delirium. | Moderate-High — avoid in elderly; monitor anticholinergic load |
| CYP2D6 Inhibitors (fluoxetine, paroxetine, bupropion, quinidine) | Inhibit amitriptyline metabolism, leading to elevated plasma levels and increased toxicity risk. | Moderate-High — dose adjustment may be required; consider plasma level monitoring |
Warnings & Contraindications
Contraindications
- Concurrent use of MAO inhibitors (or within 14 days of MAOI discontinuation)
- Acute recovery phase following myocardial infarction
- Hypersensitivity to amitriptyline or other TCAs
- Known QT prolongation or congenital long QT syndrome
Black Box Warning: Suicidality
The FDA requires a black box warning for all antidepressants regarding increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults up to age 25, particularly during the first few months of treatment or after dose changes. Patients in this age group require close monitoring, especially at treatment initiation. Amitriptyline is not approved for use in pediatric patients for depression.
Beers Criteria — Elderly Patients
The American Geriatrics Society Beers Criteria classifies amitriptyline as potentially inappropriate for adults 65 and older. Tricyclic antidepressants carry particularly high anticholinergic and sedation burdens, which increase the risk of falls, fractures, confusion, urinary retention, delirium, and cardiovascular events in elderly patients. Safer antidepressants such as SSRIs or SNRIs should be used in this population when possible.
Cardiac Monitoring
A baseline ECG is recommended before initiating amitriptyline in patients with pre-existing cardiac disease, those over 50, or those taking other QT-prolonging medications. Periodic ECG monitoring may be warranted during treatment, especially at higher doses. The QRS duration is a key marker in overdose toxicity — widening beyond 100 ms predicts arrhythmia risk.
Check for serotonin syndrome risk, QT prolongation, or other interactions with amitriptyline.
Check Drug Interactions →Frequently Asked Questions
Is amitriptyline addictive?
Amitriptyline is not considered addictive or a controlled substance. It does not produce euphoria or drug-seeking behavior. However, abrupt discontinuation after prolonged use can cause withdrawal-like symptoms including nausea, headache, flu-like symptoms, insomnia, and irritability — a syndrome sometimes called antidepressant discontinuation syndrome. For this reason, amitriptyline should always be tapered gradually under medical supervision rather than stopped suddenly.
Why is amitriptyline on the Beers Criteria list?
The American Geriatrics Society Beers Criteria lists amitriptyline as potentially inappropriate for adults 65 and older because of its potent anticholinergic and sedating properties. In elderly patients, these effects substantially increase the risk of confusion, delirium, falls, fractures, urinary retention, constipation, and dangerous drug-drug interactions. Older adults also clear the drug more slowly, leading to accumulation and toxicity at standard doses. Safer alternatives exist for depression and neuropathic pain in this population.
Can amitriptyline cause heart problems?
Yes — amitriptyline has significant cardiac effects. It prolongs the QT interval, can cause conduction defects (PR prolongation, QRS widening), and in overdose can cause life-threatening ventricular arrhythmias and heart block. This narrow therapeutic index makes amitriptyline one of the most dangerous drugs in overdose — tricyclic antidepressant overdose is a medical emergency. Even at therapeutic levels, baseline ECG monitoring is warranted in patients with pre-existing cardiac conditions.